These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30570843)

  • 21. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
    Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Biomarkers for Prostate Cancer Detection and Prognosis.
    Filella X; Foj L
    Adv Exp Med Biol; 2018; 1095():15-39. PubMed ID: 30229547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized prostate cancer screening: improving PSA tests with genomic information.
    Witte JS
    Sci Transl Med; 2010 Dec; 2(62):62ps55. PubMed ID: 21160075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smarter screening for prostate cancer.
    Tan GH; Nason G; Ajib K; Woon DTS; Herrera-Caceres J; Alhunaidi O; Perlis N
    World J Urol; 2019 Jun; 37(6):991-999. PubMed ID: 30859272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis.
    Rodriguez JF; Eggener SE
    Radiol Clin North Am; 2018 Mar; 56(2):187-196. PubMed ID: 29420975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection, PSA screening, and management of overdiagnosis.
    Borza T; Konijeti R; Kibel AS
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
    Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
    PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
    Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
    Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer screening.
    Ragsdale JW; Halstater B; Martinez-Bianchi V
    Prim Care; 2014 Jun; 41(2):355-70. PubMed ID: 24830612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel biomarkers and genomic tests in prostate cancer: a critical analysis.
    Falzarano SM; Ferro M; Bollito E; Klein EA; Carrieri G; Magi-Galluzzi C
    Minerva Urol Nefrol; 2015 Sep; 67(3):211-31. PubMed ID: 26054411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and predictive biomarkers in prostate cancer.
    Kontos CK; Adamopoulos PG; Scorilas A
    Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.